| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
|---|---|---|---|---|---|---|
| 2006 | Functional MR imaging of tumor angiogenesis predicts outcome of patients with acute myeloid leukemia [5] | TIFFANY TING-FANG SHIH ; Tien H.-F.; Liu C.-Y.; Su W.-P.; Chan W.-K.; Yang P.-C. | Leukemia | 14 | 12 | |
| 2006 | Functional MR imaging of tumor angiogenesis predicts outcome of patients with acute myeloid leukemia [5] | Shih T.T.-F.; Tien H.-F.; Liu C.-Y.; Su W.-P.; Chan W.-K.; PAN-CHYR YANG | Leukemia | 12 | ||
| 2006 | Functional MR imaging of tumor angiogenesis predicts outcome of patients with acute myeloid leukemia [5] | Shih T.T.-F.; HWEI-FANG TIEN ; Liu C.-Y.; Su W.-P.; Chan W.-K.; Yang P.-C. | Leukemia | 12 | ||
| 2005 | Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status | Su W.-P.; Yang C.-H.; Yu C.-J.; Shih J.-Y.; Chiun Hsu ; Yang P.-C. | Journal of the Formosan Medical Association | 12 | 10 | |
| 2005 | Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status | Su W.-P.; Yang C.-H.; CHONG-JEN YU ; Shih J.-Y.; Hsu C.; Yang P.-C. | Journal of the Formosan Medical Association | 12 | 10 | |
| 2005 | Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status | Su W.-P.; Yang C.-H.; Yu C.-J.; JIN-YUAN SHIH ; Hsu C.; Yang P.-C. | Journal of the Formosan Medical Association | 12 | 10 | |
| 2005 | Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status | Su W.-P.; Yang C.-H.; Yu C.-J.; Shih J.-Y.; Hsu C.; PAN-CHYR YANG | Journal of the Formosan Medical Association | 10 | ||
| 2005 | Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients | Su W.-P.; Wen C.-C.; Hsiung C.A.; Su I.-J.; Cheng A.-L.; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; CHIH-HUNG HSU ; Lu Y.-S.; Tien H.-F.; Chao T.-Y.; Chen L.-T.; Whang-Peng J.; Chen P.-J. | World Journal of Gastroenterology | 17 | 13 | |
| 2005 | Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients | Su W.-P.; Wen C.-C.; Hsiung C.A.; Su I.-J.; Cheng A.-L.; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; Hsu C.-H.; Lu Y.-S.; HWEI-FANG TIEN ; Chao T.-Y.; Chen L.-T.; Whang-Peng J.; Chen P.-J. | World Journal of Gastroenterology | 13 | ||
| 2014 | A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies | Lin C.-C.; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU ; Su W.-P.; Yeh K.-H.; Lu Y.-S.; Cheng A.-L.; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. | British Journal of Cancer | 49 | 54 | |
| 2014 | A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies | Lin C.-C.; Su W.-C.; Yen C.-J.; Hsu C.-H.; Su W.-P.; KUN-HUEI YEH ; Lu Y.-S.; Cheng A.-L.; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. | British Journal of Cancer | 54 | ||
| 2012 | Rather than interleukin-27, interleukin-6 expresses positive correlation with liver severity in naïve hepatitis B infection patients | Kao J.-T.; Lai H.-C.; Tsai S.-M.; Lin P.-C.; Chuang P.-H.; Yu C.-J.; Cheng K.-S.; Su W.-P.; PING-NING HSU ; Peng C.-Y.; Wu Y.-Y. | Liver International | 37 | ||
| 2014 | Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer | Wang C.-Y.; Chao T.-T.; Tai W.-T.; Chang F.-Y.; Su W.-P.; Chen Y.-L.; Chen P.-T.; Weng C.-Y.; ANG YUAN ; Shiau C.-W.; Yu C.-J.; Chen K.-F. | Journal of Thoracic Oncology | 8 | 9 | |
| 2014 | Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer | Wang C.-Y.; Chao T.-T.; Tai W.-T.; Chang F.-Y.; Su W.-P.; Chen Y.-L.; Chen P.-T.; Weng C.-Y.; Yuan A.; Shiau C.-W.; CHONG-JEN YU ; Chen K.-F. | Journal of Thoracic Oncology | 8 | 9 | |
| 2006 | Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer | Yang C.-H.; Shih J.-Y.; Chen K.-C.; Yu C.-J.; Yang T.-Y.; Lin C.-P.; Su W.-P.; Gow C.-H.; Chiun Hsu ; Chang G.-C.; Yang P.-C. | Cancer | 55 | 48 | |
| 2006 | Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer | Yang C.-H.; Shih J.-Y.; Chen K.-C.; CHONG-JEN YU ; Yang T.-Y.; Lin C.-P.; Su W.-P.; Gow C.-H.; Hsu C.; Chang G.-C.; Yang P.-C. | Cancer | 55 | ||
| 2006 | Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer | Yang C.-H.; JIN-YUAN SHIH ; Chen K.-C.; Yu C.-J.; Yang T.-Y.; Lin C.-P.; Su W.-P.; Gow C.-H.; Hsu C.; Chang G.-C.; Yang P.-C. | Cancer | 55 | 49 | |
| 2006 | Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer | Yang C.-H.; Shih J.-Y.; Chen K.-C.; Yu C.-J.; Yang T.-Y.; Lin C.-P.; Su W.-P.; Gow C.-H.; Hsu C.; Chang G.-C.; PAN-CHYR YANG | Cancer | 49 |
